Please wait a minute...
European Journal of Gynaecological Oncology  2017, Vol. 38 Issue (6): 883-889    DOI: 10.12892/ejgo3526.2017
Original Research Previous articles | Next articles
The long non-coding RNA UCA1, as a prognostic biomarker for high grade serous ovarian carcinoma
H.Y. Xu1, Y. Wang1, H. Zhang1, J. Xu2, *()
1 Department of Gynecology and Obstetrics, Jining NO.1 People's Hospital, Jining, China
2 Department of Emergency, The First Affiliated Hospital of Xi'An Jiaotong University, Xi'an, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of investigation: Long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) has been found to be upregulated in number of cancers; however, the contributions of UCA1 to high grade serous ovarian carcinoma (HGSOC) remain largely unknown. The aim of the current study was to investigate the clinical significance and biological function of UCA1 in HGSOC. Materials and Methods: Detectable or altered level of UCA1 was evaluated in HGSOC tissue and cell lines using quantitative real-time polymerase chain reaction. The potential relationship between UCA1 levels in tumour tissues and the clinico-pathological features of HGSOC was further established by using cell motility and invasion assay, apoptosis analysis, and cell cycle analysis. Results: The present results demonstrated that UCA1 levels are markedly increased in HGSOC tissues and correlated with larger tumour size, less differentiated histology, prognosis, and greater tumour depth. Conclusion: Data from this study suggests an important role for UCA1 in the molecular etiology, diagnosis, and progression of HGSOC.
Key words:  Ovarian cancer      Urothelial carcinoma-associated-1      High grade serous ovarian carcinoma      Gynaecological cancers     
Published:  10 December 2017     
*Corresponding Author(s):  J. XU     E-mail:  xujingbvc@hotmail.com

Cite this article: 

H.Y. Xu, Y. Wang, H. Zhang, J. Xu. The long non-coding RNA UCA1, as a prognostic biomarker for high grade serous ovarian carcinoma. European Journal of Gynaecological Oncology, 2017, 38(6): 883-889.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3526.2017     OR     https://ejgo.imrpress.com/EN/Y2017/V38/I6/883

[1] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[2] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[3] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[4] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[5] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[6] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
[7] C.J. Heesterbeek, A.M. Thijs, R.H.M. Hermans, D. Boll, G.-J. Creemers. Bevacizumab in combination with metronomic oral cyclophosphamide: an effective and well-tolerated treatment for patients with recurrent ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 364-367.
[8] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[9] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[10] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[11] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[12] L.D. Gutierrez-Castañeda, J.F. Polo, C. Carmona, D. Sanabria, D.M. Caballero, A. Jutinico, R. Parra-Medina. Expression of heat shock protein Hsp 27 in ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 221-226.
[13] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[14] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[15] X.W. Wang, J.W. Tian, L.L. Fan, R.H. Wang. The diagnostic value of color Doppler ultrasound on ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 273-276.
No Suggested Reading articles found!